06359nam 22008895 450 991029826790332120220727194510.03-319-20825-X10.1007/978-3-319-20825-1(CKB)3710000000479184(EBL)4178347(SSID)ssj0001583189(PQKBManifestationID)16258188(PQKBTitleCode)TC0001583189(PQKBWorkID)14861988(PQKB)10842333(DE-He213)978-3-319-20825-1(MiAaPQ)EBC4178347(PPN)190532556(EXLCZ)99371000000047918420150925d2015 u| 0engur|n#---|||||txtccrEndocannabinoids /edited by Roger G. Pertwee1st ed. 2015.Cham :Springer International Publishing :Imprint: Springer,2015.1 online resource (477 p.)Handbook of Experimental Pharmacology,0171-2004 ;231Description based upon print version of record.3-319-20824-1 Includes bibliographical references at the end of each chapters and index.Preface; The Endocannabinoid System: A Look Back and Ahead; Contents; Endocannabinoids and Their Pharmacological Actions; 1 Introduction; 2 Evidence That Certain Endogenous Compounds Target Cannabinoid Receptors Orthosterically; 2.1 Evidence from Binding Assays; 2.2 Evidence from Two Functional Bioassays; 2.2.1 [35S]GTPgammaS Binding Assay; 2.2.2 Cyclic AMP Assay; 3 Non-Cannabinoid Receptors and Channels Targeted by Endogenous Cannabinoid Receptor Ligands at Submicromolar Concentrations; 3.1 Non-Cannabinoid G Protein-Coupled Receptors; 3.1.1 GPR55; 3.2 Ligand-Gated Ion Channels3.2.1 5-HT3 Receptors3.2.2 Nicotinic Acetylcholine Receptors; 3.2.3 Glycine Receptors; 3.2.4 Ionotropic Glutamate NMDA Receptors; 3.3 Transient Receptor Potential Channels; 3.3.1 TRPV1; 3.3.2 TRPM8 Channels; 3.4 Voltage-Gated Calcium Channels; 3.4.1 T-Type Cav3 Calcium Channels; 3.5 Potassium Channels; 3.5.1 ATP-Sensitive Inward Rectifier KATP Channels of the 2TM Domain Family; 3.5.2 Voltage-Gated Kv and KCa Channels of the 6TM Domain Family; 4 Allosteric Endocannabinoids; 5 Conclusions; References; Biosynthesis and Fate of Endocannabinoids1 Endocannabinoids and Endocannabinoid-Like Compounds2 Biosynthesis of the Endocannabinoids; 3 Uptake of the Endocannabinoids: Proposed Mechanisms; 4 Degradation of the Endocannabinoids; 4.1 FAAH and NAAA; 4.2 MGL, ABHD6 and ABHD12; 5 Conclusions; References; Distribution of the Endocannabinoid System in the Central Nervous System; 1 Introduction; 1.1 Overview; 1.2 Cells Expressing Components of the ECS; 1.3 Subcellular Localization of CB1 Cannabinoid Receptors; 2 Retina; 2.1 Receptors; 2.2 Synthetic Enzymes; 2.3 Degradative Enzymes; 3 Cerebral Cortex; 3.1 Neocortex; 3.1.1 Receptors3.1.2 Synthetic Enzymes3.1.3 Degradative Enzymes; 3.2 Olfactory Areas (Olfactory Bulb, Piriform Cortex, Associated Regions); 3.2.1 Receptors; 3.2.2 Synthetic Enzymes; 3.2.3 Degradative Enzymes; 3.3 Hippocampal Formation; 3.3.1 Receptors; 3.3.2 Synthetic Enzymes; 3.3.3 Degradative Enzymes; 3.4 Cortical Subplate (Other Amygdala Nuclei); 3.4.1 Receptors; 3.4.2 Synthetic Enzymes; 3.4.3 Degradative Enzymes; 4 Subcortical Nuclei (Striatum, Basal Ganglia); 4.1 Striatum (Dorsal, Caudate); 4.1.1 Receptors; 4.1.2 Synthetic Enzymes; 4.1.3 Degradative Enzymes; 4.2 Striatum (Ventral, Accumbens)4.2.1 Receptors4.2.2 Synthetic Enzymes; 4.2.3 Degradative Enzymes; 4.3 Striatum Medial (Lateral Septum, Septohippocampal, etc.); 4.3.1 Receptors; 4.3.2 Synthetic Enzymes; 4.3.3 Degradative Enzymes; 4.4 Striatum Caudal (Striatum-like Amygdala Nuclei, Central Amygdala, Bed Nucleus, Medial Amygdala, Etc.); 4.4.1 Receptors; 5 Cerebellum and Associated Nuclei; 5.1 Cerebellar Cortex; 5.1.1 Receptors; 5.1.2 Synthetic Enzymes; 5.1.3 Degradative Enzymes; 5.2 Deep Cerebellar Nuclei (Fastigial, Interpos, Dentate Nucleus); 5.2.1 Receptors; 5.2.2 Synthetic Enzymes; 5.2.3 Degradative Enzymes; 6 Brainstem6.1 DiencephalonThere is currently considerable interest in the development of medicines that would enhance endocannabinoid-induced “autoprotection”, for example through inhibition of endocannabinoid metabolizing enzymes or cellular uptake processes or that would oppose endocannabinoid-induced “autoimpairment”. This volume describes the physiology, pathophysiology and pharmacology of the endocannabinoid system and potential strategies for targeting this system in the clinic.Handbook of Experimental PharmacologyPharmacologyCell biologyNeurosciencesPsychopharmacologyImmunologyCytokinesGrowth factorsPharmacology/Toxicologyhttps://scigraph.springernature.com/ontologies/product-market-codes/B21007Cell Biologyhttps://scigraph.springernature.com/ontologies/product-market-codes/L16008Neuroscienceshttps://scigraph.springernature.com/ontologies/product-market-codes/B18006Psychopharmacologyhttps://scigraph.springernature.com/ontologies/product-market-codes/H53010Immunologyhttps://scigraph.springernature.com/ontologies/product-market-codes/B14000Cytokines and Growth Factorshttps://scigraph.springernature.com/ontologies/product-market-codes/L14120Pharmacology.Cell biology.Neurosciences.Psychopharmacology.Immunology.Cytokines.Growth factors.Pharmacology/Toxicology.Cell Biology.Neurosciences.Psychopharmacology.Immunology.Cytokines and Growth Factors.615.7827Pertwee Roger Gedthttp://id.loc.gov/vocabulary/relators/edtMiAaPQMiAaPQMiAaPQBOOK9910298267903321Endocannabinoids1383799UNINA